Do analysts rate ZIVO or MBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ZIVO or MBIO more profitable?

ZIVO Bioscience's return on equity of 0.00% beat Mustang Bio's return on equity. Company Net Margins Return on Equity Return on Assets ZIVO Bioscience N/A N/A -2,240.92% Mustang Bio N/A -35.38% -16.36%

Do analysts recommend AIXC or MBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, AIXC or MBIO?

Mustang Bio is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qualigen Therapeutics N/A N/A -$16.97M -$6.47 N/A Mustang Bio N/A N/A -$1.92M -$0.48 N/A

Is AIXC or MBIO more profitable?

Mustang Bio's return on equity of -35.38% beat Qualigen Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Qualigen Therapeutics N/A -771.52% -79.52% Mustang Bio N/A -35.38% -16.36%

Do analysts recommend ATOS or MBIO?

Atossa Genetics presently has a consensus target price of $20.33, indicating a potential upside of 784.06%. Given Atossa Genetics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Atossa Genetics is more favorable than Mustang Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atossa Genetics 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20 Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, ATOS or MBIO?

Mustang Bio is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atossa Genetics N/A N/A -$34.77M -$3.21 N/A Mustang Bio N/A N/A -$1.92M -$0.48 N/A

Is ATOS or MBIO more profitable?

Mustang Bio's return on equity of -35.38% beat Atossa Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Atossa Genetics N/A -84.91% -72.36% Mustang Bio N/A -35.38% -16.36%

Do analysts recommend MBIO or LGVN?

Longeveron has a consensus price target of $5.50, indicating a potential upside of 816.67%. Given Longeveron's stronger consensus rating and higher possible upside, analysts plainly believe Longeveron is more favorable than Mustang Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Longeveron 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is MBIO or LGVN more profitable?

Mustang Bio has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. Mustang Bio's return on equity of -35.38% beat Longeveron's return on equity. Company Net Margins Return on Equity Return on Assets Mustang Bio N/A -35.38% -16.36% Longeveron -1,844.49% -202.41% -140.67%

Do analysts rate NEUP or MBIO?

Neuphoria Therapeutics presently has a consensus target price of $21.00, indicating a potential upside of 476.92%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Neuphoria Therapeutics is more favorable than Mustang Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuphoria Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NEUP or MBIO more profitable?

Mustang Bio's return on equity of -35.38% beat Neuphoria Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neuphoria Therapeutics N/A -76.93% -54.76% Mustang Bio N/A -35.38% -16.36%

Mustang Bio (MBIO) Competitors

$0.56 -0.01 (-1.42%)

As of 07/24/2026 04:00 PM Eastern

Compare

MBIO vs. ZIVO, AIXC, ATOS, LGVN, and NEUP

Should you buy Mustang Bio stock or one of its competitors? MarketBeat compares Mustang Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mustang Bio include ZIVO Bioscience (ZIVO), Qualigen Therapeutics (AIXC), Atossa Genetics (ATOS), Longeveron (LGVN), and Neuphoria Therapeutics (NEUP). These companies are all part of the "pharmaceutical products" industry.

How does Mustang Bio compare to ZIVO Bioscience?

ZIVO Bioscience (NASDAQ:ZIVO) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

ZIVO Bioscience's return on equity of 0.00% beat Mustang Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Mustang Bio	N/A	-35.38%	-16.36%

Mustang Bio has lower revenue, but higher earnings than ZIVO Bioscience. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	1,309.78	-$7.78M	-$1.71	N/A
Mustang Bio	N/A	N/A	-$1.92M	-$0.48	N/A

ZIVO Bioscience has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market. Comparatively, Mustang Bio has a beta of 2.05, indicating that its share price is 105% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Mustang Bio had 2 more articles in the media than ZIVO Bioscience. MarketBeat recorded 2 mentions for Mustang Bio and 0 mentions for ZIVO Bioscience. Mustang Bio's average media sentiment score of 1.43 beat ZIVO Bioscience's score of 0.00 indicating that Mustang Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
ZIVO Bioscience	Neutral
Mustang Bio	Positive

12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 10.0% of Mustang Bio shares are owned by institutional investors. 48.9% of ZIVO Bioscience shares are owned by insiders. Comparatively, 4.0% of Mustang Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Mustang Bio beats ZIVO Bioscience on 7 of the 12 factors compared between the two stocks.

How does Mustang Bio compare to Qualigen Therapeutics?

Qualigen Therapeutics (NASDAQ:AIXC) and Mustang Bio (NASDAQ:MBIO) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

Mustang Bio is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A
Mustang Bio	N/A	N/A	-$1.92M	-$0.48	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Mustang Bio had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 2 mentions for Mustang Bio and 1 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 1.87 beat Mustang Bio's score of 1.43 indicating that Qualigen Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Qualigen Therapeutics	Very Positive
Mustang Bio	Positive

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 10.0% of Mustang Bio shares are owned by institutional investors. 1.2% of Qualigen Therapeutics shares are owned by company insiders. Comparatively, 4.0% of Mustang Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Qualigen Therapeutics has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, Mustang Bio has a beta of 2.05, indicating that its stock price is 105% more volatile than the broader market.

Mustang Bio's return on equity of -35.38% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	-771.52%	-79.52%
Mustang Bio	N/A	-35.38%	-16.36%

Summary

Mustang Bio beats Qualigen Therapeutics on 8 of the 10 factors compared between the two stocks.

How does Mustang Bio compare to Atossa Genetics?

Atossa Genetics (NASDAQ:ATOS) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

In the previous week, Atossa Genetics and Atossa Genetics both had 2 articles in the media. Mustang Bio's average media sentiment score of 1.43 beat Atossa Genetics' score of 0.94 indicating that Mustang Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Atossa Genetics	Positive
Mustang Bio	Positive

Atossa Genetics presently has a consensus target price of $20.33, indicating a potential upside of 784.06%. Given Atossa Genetics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Atossa Genetics is more favorable than Mustang Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mustang Bio is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A
Mustang Bio	N/A	N/A	-$1.92M	-$0.48	N/A

Mustang Bio's return on equity of -35.38% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-84.91%	-72.36%
Mustang Bio	N/A	-35.38%	-16.36%

Atossa Genetics has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market. Comparatively, Mustang Bio has a beta of 2.05, meaning that its stock price is 105% more volatile than the broader market.

12.7% of Atossa Genetics shares are held by institutional investors. Comparatively, 10.0% of Mustang Bio shares are held by institutional investors. 9.8% of Atossa Genetics shares are held by company insiders. Comparatively, 4.0% of Mustang Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Atossa Genetics and Mustang Bio tied by winning 6 of the 12 factors compared between the two stocks.

How does Mustang Bio compare to Longeveron?

Mustang Bio (NASDAQ:MBIO) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

Mustang Bio has higher earnings, but lower revenue than Longeveron. Mustang Bio is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mustang Bio	N/A	N/A	-$1.92M	-$0.48	N/A
Longeveron	$1.22M	15.37	-$22.70M	-$1.13	N/A

Mustang Bio has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. Mustang Bio's return on equity of -35.38% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mustang Bio	N/A	-35.38%	-16.36%
Longeveron	-1,844.49%	-202.41%	-140.67%

Longeveron has a consensus price target of $5.50, indicating a potential upside of 816.67%. Given Longeveron's stronger consensus rating and higher possible upside, analysts plainly believe Longeveron is more favorable than Mustang Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Longeveron	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

10.0% of Mustang Bio shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 4.0% of Mustang Bio shares are owned by company insiders. Comparatively, 7.4% of Longeveron shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Longeveron had 1 more articles in the media than Mustang Bio. MarketBeat recorded 3 mentions for Longeveron and 2 mentions for Mustang Bio. Mustang Bio's average media sentiment score of 1.43 beat Longeveron's score of 0.97 indicating that Mustang Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Mustang Bio	Positive
Longeveron	Positive

Mustang Bio has a beta of 2.05, suggesting that its stock price is 105% more volatile than the broader market. Comparatively, Longeveron has a beta of -0.35, suggesting that its stock price is 135% less volatile than the broader market.

Summary

Longeveron beats Mustang Bio on 8 of the 15 factors compared between the two stocks.

How does Mustang Bio compare to Neuphoria Therapeutics?

Neuphoria Therapeutics (NASDAQ:NEUP) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

15.9% of Neuphoria Therapeutics shares are held by institutional investors. Comparatively, 10.0% of Mustang Bio shares are held by institutional investors. 1.5% of Neuphoria Therapeutics shares are held by company insiders. Comparatively, 4.0% of Mustang Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Neuphoria Therapeutics presently has a consensus target price of $21.00, indicating a potential upside of 476.92%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Neuphoria Therapeutics is more favorable than Mustang Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Neuphoria Therapeutics has higher earnings, but lower revenue than Mustang Bio. Mustang Bio is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	-$13.27K	-1,482.94	-$370K	-$11.06	N/A
Mustang Bio	N/A	N/A	-$1.92M	-$0.48	N/A

Mustang Bio's return on equity of -35.38% beat Neuphoria Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-76.93%	-54.76%
Mustang Bio	N/A	-35.38%	-16.36%

Neuphoria Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Mustang Bio has a beta of 2.05, indicating that its stock price is 105% more volatile than the broader market.

In the previous week, Neuphoria Therapeutics had 6 more articles in the media than Mustang Bio. MarketBeat recorded 8 mentions for Neuphoria Therapeutics and 2 mentions for Mustang Bio. Mustang Bio's average media sentiment score of 1.43 beat Neuphoria Therapeutics' score of 0.45 indicating that Mustang Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Neuphoria Therapeutics	Neutral
Mustang Bio	Positive

Summary

Neuphoria Therapeutics and Mustang Bio tied by winning 7 of the 14 factors compared between the two stocks.

Get Mustang Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBIO vs. The Competition

Export

Metric	Mustang Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.32M	$3.67B	$6.86B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-1.17	21.48	27.14	23.64
Price / Sales	N/A	169.92	517.01	89.03
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	0.43	7.88	10.28	6.07
Net Income	-$1.92M	$23.86M	$3.60B	$331.99M
7 Day Performance	-10.54%	-3.82%	-1.27%	-0.63%
1 Month Performance	-16.16%	-2.61%	-0.37%	-2.00%
1 Year Performance	-70.58%	32.79%	18.30%	13.62%

Mustang Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBIO Mustang Bio	1.3982 of 5 stars	$0.56 -1.4%	N/A	-72.3%	$4.26M	N/A	N/A	100	Positive News Short Interest Decrease
ZIVO ZIVO Bioscience	N/A	$4.83 flat	N/A	-55.4%	$20.05M	$15.85K	N/A	10
AIXC Qualigen Therapeutics	0.2468 of 5 stars	$0.99 +7.6%	N/A	N/A	$20.04M	N/A	N/A	50	Positive News Analyst Forecast Gap Down
ATOS Atossa Genetics	2.2367 of 5 stars	$2.26 -5.8%	$20.33 +799.7%	-82.2%	$19.46M	N/A	N/A	8
LGVN Longeveron	2.3188 of 5 stars	$0.62 -1.4%	$5.50 +783.8%	-64.5%	$19.39M	$1.20M	N/A	20	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBIO) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mustang Bio (MBIO) Competitors

MBIO vs. ZIVO, AIXC, ATOS, LGVN, and NEUP

How does Mustang Bio compare to ZIVO Bioscience?

Summary

How does Mustang Bio compare to Qualigen Therapeutics?

Summary

How does Mustang Bio compare to Atossa Genetics?

Summary

How does Mustang Bio compare to Longeveron?

Summary

How does Mustang Bio compare to Neuphoria Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBIO vs. The Competition

Mustang Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mustang Bio (MBIO) Competitors

MBIO vs. ZIVO, AIXC, ATOS, LGVN, and NEUP

How does Mustang Bio compare to ZIVO Bioscience?

Is ZIVO or MBIO more profitable?

Which has stronger earnings & valuation, ZIVO or MBIO?

Which has more volatility and risk, ZIVO or MBIO?

Do analysts rate ZIVO or MBIO?

Does the media favor ZIVO or MBIO?

Do institutionals & insiders have more ownership in ZIVO or MBIO?

Summary

How does Mustang Bio compare to Qualigen Therapeutics?

Which has better valuation & earnings, AIXC or MBIO?

Do analysts recommend AIXC or MBIO?

Does the media refer more to AIXC or MBIO?

Do institutionals and insiders have more ownership in AIXC or MBIO?

Which has more volatility & risk, AIXC or MBIO?

Is AIXC or MBIO more profitable?

Summary

How does Mustang Bio compare to Atossa Genetics?

Does the media favor ATOS or MBIO?

Do analysts recommend ATOS or MBIO?

Which has higher valuation and earnings, ATOS or MBIO?

Is ATOS or MBIO more profitable?

Which has more risk & volatility, ATOS or MBIO?

Do insiders & institutionals believe in ATOS or MBIO?

Summary

How does Mustang Bio compare to Longeveron?

Which has better valuation and earnings, MBIO or LGVN?

Is MBIO or LGVN more profitable?

Do analysts recommend MBIO or LGVN?

Do insiders and institutionals believe in MBIO or LGVN?

Does the media refer more to MBIO or LGVN?

Which has more volatility & risk, MBIO or LGVN?

Summary

How does Mustang Bio compare to Neuphoria Therapeutics?

Do insiders & institutionals believe in NEUP or MBIO?

Do analysts rate NEUP or MBIO?

Which has preferable valuation and earnings, NEUP or MBIO?

Is NEUP or MBIO more profitable?

Which has more volatility & risk, NEUP or MBIO?

Does the media prefer NEUP or MBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBIO vs. The Competition

Mustang Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools